Gewinn- und Verlustrechnung von Viking Therapeutics, Inc.

Get 'em while they're still on sale. Catalysts are on the horizon.

Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.

Viking Therapeutics raised $575 million in a supplementary public offering after positive trial results. Share dilution reduces EPS by about 7.2%, and the earnings yield per dollar invested is now 14.4% lower.

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $30.51, moving 6.41% from the previous trading session.

Could this be what Novo needs to turn things around?

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $32.74, signifying a +2.92% move from its prior day's close.

Viking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. The medicine could eventually become a notable player in the weight-loss market.

Viking Therapeutics' recent clinical trial results for its leading weight loss candidate were excellent. But Eli Lilly, the leader in this area, has a robust pipeline of its own and has little to fear from its smaller rival.

Investors looking for some compelling growth opportunities outside of tech may want to consider these stocks.

Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of $35.00 per share, and $258.75 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"), which included the full exercise by the underwriters of the common stock offering of their option to purchase an additional 1,178,571 shares of common stock, and the full exercise by the underwriters of the note offering of their option to purchase an additional $33.75 million aggregate principal amount of notes.